Literature DB >> 22504640

Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.

Yuan Hong1, Yibing Peng, Haiyan Xiao, Michael Mi, David Munn, Yukai He.   

Abstract

A major problem with current cancer vaccines is that the induction of CD8 immune responses is rarely associated with antitumor benefits, mainly owing to multiple immune suppressions in established tumor lesions. In this study, we investigated if and how activation of endogenous CD4 T cells could be achieved to influence the suppressive tumor milieu and antitumor effect. We engineered a lentivector (lv) to express a nominal fusion Ag composed of hepatitis B surface protein and IgG2a Fc fragment (HBS-Fc-lv) to increase the magnitude of CD8 response but, more importantly, to induce effective coactivation of CD4 T cells. We found that, remarkably, immunization with HBS-Fc-lv caused significant regression of established tumors. Immunologic analysis revealed that, compared with HBS-lv without Fc fragment, immunization with HBS-Fc-lv markedly increased the number of functional CD8 and CD4 T cells and the level of Th1/Tc1-like cytokines in the tumor while substantially decreasing the regulatory T cell ratio. The favorable immunologic changes in tumor lesions and the improvement of antitumor effects from HBS-Fc-lv immunization were dependent on the CD4 activation, which was Fc receptor mediated. Adoptive transfer of CD4 T cells from the HBS-Fc-lv-immunized mice could activate endogenous CD8 T cells in an IFN-γ-dependent manner. We conclude that endogenous CD4 T cells can be activated by lv expressing Fc-tagged Ag to provide another layer of help--that is, creating a Th1/Tc1-like proinflammatory milieu within the tumor lesion to boost the effector phase of immune responses in enhancing the antitumor effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504640      PMCID: PMC3358827          DOI: 10.4049/jimmunol.1103512

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Authors:  Christoph Esslinger; Laurence Chapatte; Daniela Finke; Isabelle Miconnet; Philippe Guillaume; Frédéric Lévy; H Robson MacDonald
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.

Authors:  Michael R Betts; Jason M Brenchley; David A Price; Stephen C De Rosa; Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

3.  Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Authors:  Yuan Hong; Yibing Peng; Michael Mi; Haiyan Xiao; David H Munn; Gui-Qiang Wang; Yukai He
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

Review 4.  Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.

Authors:  Robert A Seder; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-09       Impact factor: 25.606

Review 5.  T-cell epitope peptide vaccines.

Authors:  Sherine F Elsawa; David A Rodeberg; Esteban Celis
Journal:  Expert Rev Vaccines       Date:  2004-10       Impact factor: 5.217

6.  Gastrointestinal dendritic cells promote Th2 skewing via OX40L.

Authors:  Ana Belén Blázquez; M Cecilia Berin
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

7.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

8.  Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants.

Authors:  Reinhold Schirmbeck; Nektarios Dikopoulos; Marcin Kwissa; Frank Leithäuser; Kasper Lamberth; Soren Buus; Karl Melber; Jörg Reimann
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

Review 9.  Multiple roles for CD4+ T cells in anti-tumor immune responses.

Authors:  Richard Kennedy; Esteban Celis
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

10.  Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.

Authors:  Hugh D Goold; David Escors; Thomas J Conlan; Ronjon Chakraverty; Clare L Bennett
Journal:  J Immunol       Date:  2011-03-09       Impact factor: 5.422

View more
  2 in total

1.  Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution in a murine model.

Authors:  Ana Barahona Afonso; Lígia Neves Justo; Ana Cristina Queirós; Constantin Fesel; Maria Salomé Cabral; Maria Gomes da Silva; Luis Porrata; Svetomir Markovic; Ana Elisabete Pires; Cristina João
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

2.  Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Authors:  Haiyan Xiao; Yibing Peng; Yuan Hong; Lei Huang; Z Sheng Guo; David L Bartlett; Ning Fu; David H Munn; Andrew Mellor; Yukai He
Journal:  J Immunol       Date:  2013-04-22       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.